IRB #

STUDY00022759

Title

[NCI CIRB] S1931: PHASE III TRIAL OF IMMUNOTHERAPY-BASED COMBINATION THERAPY WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA (PROBE TRIAL)

Principal Investigator

Christopher Ryan

Study Purpose

The purpose of this study is to compare any good and bad effects of performing surgery to reduce the amount of cancer in the body. We wish to understand the effects of starting drug therapy followed by possible surgery and then more drug therapy. We are also doing this study because we want to find out if this approach is better or worse than the usual approach for kidney cancer.

Medical Condition(s)

Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma (RCC)
Immunotherapy
Nephrectomy

Eligibility Criteria

Histologically proven diagnosis of clear cell or non-clear cell renal cell carcinoma

Primary tumor in place.

Imaging showing evidence of metastatic disease.

≥ 18 years old

Must have both kidneys (transplanted kidney not acceptable).

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

7 years

Minors Included

No

Contact

Knight Information Line - trials@ohsu.edu or 503-494-1080

Sponsor

SWOG

Recruitment End

04/01/2023

Compensation Provided

No


Go Back